DNA
Ginkgo Bioworks HoldingsKey Statistics
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings (DNA) is a pioneering entity in the synthetic biology landscape, utilizing advanced genetic engineering to craft customized bioengineered organisms across various sectors, including pharmaceuticals, agriculture, and industrial biotech. The company's state-of-the-art platform bolsters cellular design for manufacturing, driving efficiency in product development and production processes. With a strategic emphasis on addressing critical global challenges such as climate change and food security, Ginkgo is uniquely positioned to make substantial contributions across multiple industries while promoting sustainable biotechnology solutions. As the demand for bio-based alternatives intensifies, Ginkgo’s innovative approach and commitment to sustainability offer a promising trajectory for significant growth and impact.
Fundamentals
| Revenue (TTM) | $151.40M |
| Gross Profit (TTM) | $105.42M |
| EBITDA | $-262.49M |
| Operating Margin | -366.50% |
| Return on Equity | -56.00% |
| Return on Assets | -16.20% |
| Revenue/Share (TTM) | $2.67 |
| Book Value | $7.19 |
| Price-to-Book | 1.18 |
| Price-to-Sales (TTM) | 3.45 |
| EV/Revenue | 3.698 |
| EV/EBITDA | -1.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -49.10% |
| Shares Outstanding | $53.36M |
| Float | $47.85M |
| % Insiders | 4.60% |
| % Institutions | 68.65% |
Historical Volatility
Volatility is currently contracting